JP2006508039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508039A5 JP2006508039A5 JP2004518039A JP2004518039A JP2006508039A5 JP 2006508039 A5 JP2006508039 A5 JP 2006508039A5 JP 2004518039 A JP2004518039 A JP 2004518039A JP 2004518039 A JP2004518039 A JP 2004518039A JP 2006508039 A5 JP2006508039 A5 JP 2006508039A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- antibody
- interferon
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 102000003996 Interferon-beta Human genes 0.000 claims 11
- 108090000467 Interferon-beta Proteins 0.000 claims 11
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 7
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 7
- 229960001388 interferon-beta Drugs 0.000 claims 7
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 102100036089 Fascin Human genes 0.000 claims 3
- 229960002806 daclizumab Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39302102P | 2002-06-28 | 2002-06-28 | |
| PCT/US2002/038290 WO2004002500A1 (en) | 2002-06-28 | 2002-11-27 | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| PCT/US2003/020428 WO2004002421A2 (en) | 2002-06-28 | 2003-06-27 | Method for the treatment of multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284862A Division JP2010132660A (ja) | 2002-06-28 | 2009-12-16 | 多発性硬化症を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508039A JP2006508039A (ja) | 2006-03-09 |
| JP2006508039A5 true JP2006508039A5 (https=) | 2006-08-03 |
Family
ID=30000962
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004517494A Withdrawn JP2005535636A (ja) | 2002-06-28 | 2002-11-27 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| JP2004518039A Withdrawn JP2006508039A (ja) | 2002-06-28 | 2003-06-27 | 多発性硬化症を治療する方法 |
| JP2009284862A Withdrawn JP2010132660A (ja) | 2002-06-28 | 2009-12-16 | 多発性硬化症を治療する方法 |
| JP2011082497A Withdrawn JP2011157378A (ja) | 2002-06-28 | 2011-04-04 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| JP2012217520A Withdrawn JP2013032372A (ja) | 2002-06-28 | 2012-09-28 | 多発性硬化症を治療する方法 |
| JP2013086246A Pending JP2013139478A (ja) | 2002-06-28 | 2013-04-17 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| JP2014147314A Expired - Lifetime JP5905534B2 (ja) | 2002-06-28 | 2014-07-18 | 多発性硬化症を治療する方法 |
| JP2016030540A Withdrawn JP2016145220A (ja) | 2002-06-28 | 2016-02-22 | 多発性硬化症を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004517494A Withdrawn JP2005535636A (ja) | 2002-06-28 | 2002-11-27 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284862A Withdrawn JP2010132660A (ja) | 2002-06-28 | 2009-12-16 | 多発性硬化症を治療する方法 |
| JP2011082497A Withdrawn JP2011157378A (ja) | 2002-06-28 | 2011-04-04 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| JP2012217520A Withdrawn JP2013032372A (ja) | 2002-06-28 | 2012-09-28 | 多発性硬化症を治療する方法 |
| JP2013086246A Pending JP2013139478A (ja) | 2002-06-28 | 2013-04-17 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| JP2014147314A Expired - Lifetime JP5905534B2 (ja) | 2002-06-28 | 2014-07-18 | 多発性硬化症を治療する方法 |
| JP2016030540A Withdrawn JP2016145220A (ja) | 2002-06-28 | 2016-02-22 | 多発性硬化症を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (11) | US7575742B2 (https=) |
| EP (3) | EP3269377A1 (https=) |
| JP (8) | JP2005535636A (https=) |
| AU (3) | AU2002368055B2 (https=) |
| CA (3) | CA2490804C (https=) |
| CY (2) | CY2016043I2 (https=) |
| DK (2) | DK1539200T3 (https=) |
| ES (2) | ES2474718T3 (https=) |
| HK (1) | HK1249850A1 (https=) |
| HU (2) | HUE036677T2 (https=) |
| IL (2) | IL165973A (https=) |
| LU (1) | LU93315I2 (https=) |
| PT (2) | PT1539200E (https=) |
| SI (2) | SI1539200T1 (https=) |
| WO (2) | WO2004002500A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261537A3 (en) * | 2001-04-26 | 2012-06-13 | Fallbrook Technologies Inc. | Continuously variable transmission |
| AU2002368055B2 (en) * | 2002-06-28 | 2008-09-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
| US20060134750A1 (en) * | 2004-03-10 | 2006-06-22 | Pepgen Corporation | Method of treatment using interferon-tau |
| AU2006204937B2 (en) | 2005-01-12 | 2011-02-10 | Biogen Ma Inc. | Method for delivering Interferon-beta |
| US20080279819A1 (en) * | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| RU2011111391A (ru) * | 2008-08-28 | 2012-10-10 | Эбботт Байотерапьютикс Корп. (Us) | Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r |
| WO2010045265A1 (en) * | 2008-10-13 | 2010-04-22 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| WO2010068923A2 (en) * | 2008-12-12 | 2010-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Agents that selectively inhibit cd25 on dendritic cells or t cells and their use |
| CA2771335A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Biotherapeutics Corp. | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
| CA2844662A1 (en) | 2011-08-08 | 2013-02-14 | Abbvie Biotherapeutics Inc. | Methods of treating progressive forms of multiple sclerosis |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| WO2018027195A1 (en) | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
| DE102017104088A1 (de) * | 2017-02-28 | 2018-08-30 | L&O Hunting Group GmbH | Integralschalldämpfer für einen Gewehrlauf |
| US12600757B2 (en) | 2017-04-07 | 2026-04-14 | Bioniz Therapeutics, Inc. | Peptides inhibiting gamma-c-cytokine activity and methods of use |
| CA3137971A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| WO2021026362A1 (en) * | 2019-08-07 | 2021-02-11 | Edifice Health, Inc. | Treatment of prevention of cardiovascular disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4819150A (en) | 1985-04-05 | 1989-04-04 | Unisys Corporation | Array for simulating computer functions for large computer systems |
| US5336489A (en) | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
| US5011684A (en) * | 1985-09-05 | 1991-04-30 | Beth Israel Hospital Association | Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB2188941B (en) | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
| US6051405A (en) * | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US5013548A (en) | 1987-09-08 | 1991-05-07 | Duke University | Production of antibodies to HIV |
| US5695927A (en) | 1988-03-31 | 1997-12-09 | The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology | Monoclonal antibodies specific for HIV and the hybridomas for production thereof |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
| US5152980A (en) | 1988-05-19 | 1992-10-06 | The Beth Israel Hospital Association | Induction of tolerance to a foreign antigen IL-2 receptor-binding substances |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
| US5840496A (en) * | 1990-10-09 | 1998-11-24 | Chiron Corporation | Method for diagnosing endometrial cancer |
| FR2672291A1 (fr) | 1991-01-31 | 1992-08-07 | Inst Nat Sante Rech Med | Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale. |
| GB9115010D0 (en) | 1991-07-11 | 1991-08-28 | Wellcome Found | Antibody |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5571507A (en) | 1992-02-25 | 1996-11-05 | Seragen, Inc. | Methods of treating diabetes |
| US5643756A (en) | 1992-08-28 | 1997-07-01 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
| EP0699077B1 (en) | 1993-05-07 | 2001-10-31 | Akzo Nobel N.V. | Hiv immunogenic complexes |
| WO1995005734A1 (en) | 1993-08-27 | 1995-03-02 | The Pillsbury Company | Mechanical gas flushing system |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| AU3710597A (en) * | 1997-08-06 | 1999-03-01 | Laboratorio Medinfar-Produtos Farmaceuticos, Lda | Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system |
| WO2000025816A1 (en) | 1998-10-30 | 2000-05-11 | The University Of Miami | Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
| US6346247B1 (en) * | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| EP1321153A4 (en) | 2000-04-25 | 2005-02-16 | Tomoaki Hoshino | DRUG SUBSTANCES INTENDED FOR INTERSTITIAL PNEUMONIA, METHOD OF CONSTRUCTING AN ANIMAL MODEL OF THE DISEASE, AND SCREENING METHOD USING THE SAME |
| CA2443405A1 (en) * | 2001-04-06 | 2002-10-17 | University Of Bristol | Use of cd25 binding molecules in steroid-resistant patients |
| AU2002368055B2 (en) * | 2002-06-28 | 2008-09-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
| AU2003251633A1 (en) | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
-
2002
- 2002-11-27 AU AU2002368055A patent/AU2002368055B2/en not_active Ceased
- 2002-11-27 WO PCT/US2002/038290 patent/WO2004002500A1/en not_active Ceased
- 2002-11-27 JP JP2004517494A patent/JP2005535636A/ja not_active Withdrawn
- 2002-11-27 US US10/519,311 patent/US7575742B2/en not_active Expired - Fee Related
- 2002-11-27 CA CA2490804A patent/CA2490804C/en not_active Expired - Lifetime
-
2003
- 2003-06-27 WO PCT/US2003/020428 patent/WO2004002421A2/en not_active Ceased
- 2003-06-27 PT PT37621810T patent/PT1539200E/pt unknown
- 2003-06-27 EP EP17175522.6A patent/EP3269377A1/en not_active Withdrawn
- 2003-06-27 SI SI200332375T patent/SI1539200T1/sl unknown
- 2003-06-27 DK DK03762181.0T patent/DK1539200T3/da active
- 2003-06-27 SI SI200332543T patent/SI2314627T1/sl unknown
- 2003-06-27 CA CA2844639A patent/CA2844639A1/en not_active Abandoned
- 2003-06-27 ES ES03762181.0T patent/ES2474718T3/es not_active Expired - Lifetime
- 2003-06-27 JP JP2004518039A patent/JP2006508039A/ja not_active Withdrawn
- 2003-06-27 DK DK10182563.6T patent/DK2314627T3/en active
- 2003-06-27 PT PT101825636T patent/PT2314627T/pt unknown
- 2003-06-27 ES ES10182563.6T patent/ES2637011T3/es not_active Expired - Lifetime
- 2003-06-27 CA CA2490186A patent/CA2490186C/en not_active Expired - Fee Related
- 2003-06-27 EP EP03762181.0A patent/EP1539200B1/en not_active Expired - Lifetime
- 2003-06-27 US US10/607,598 patent/US7258859B2/en not_active Expired - Lifetime
- 2003-06-27 HU HUE10182563A patent/HUE036677T2/hu unknown
- 2003-06-27 AU AU2003247813A patent/AU2003247813C1/en not_active Ceased
- 2003-06-27 EP EP10182563.6A patent/EP2314627B1/en not_active Expired - Lifetime
-
2004
- 2004-12-23 IL IL165973A patent/IL165973A/en active IP Right Grant
-
2007
- 2007-07-13 US US11/827,876 patent/US8454965B2/en not_active Expired - Fee Related
-
2008
- 2008-09-04 AU AU2008212004A patent/AU2008212004B2/en not_active Ceased
-
2009
- 2009-03-10 US US12/401,543 patent/US8298525B2/en not_active Expired - Fee Related
- 2009-12-16 JP JP2009284862A patent/JP2010132660A/ja not_active Withdrawn
-
2011
- 2011-04-04 JP JP2011082497A patent/JP2011157378A/ja not_active Withdrawn
-
2012
- 2012-05-18 US US13/475,688 patent/US20130017152A1/en not_active Abandoned
- 2012-09-12 US US13/612,763 patent/US8636997B2/en not_active Expired - Fee Related
- 2012-09-28 JP JP2012217520A patent/JP2013032372A/ja not_active Withdrawn
-
2013
- 2013-04-17 JP JP2013086246A patent/JP2013139478A/ja active Pending
-
2014
- 2014-07-18 JP JP2014147314A patent/JP5905534B2/ja not_active Expired - Lifetime
- 2014-09-15 US US14/487,012 patent/US20150010477A1/en not_active Abandoned
-
2015
- 2015-07-06 US US14/792,432 patent/US20150337044A1/en not_active Abandoned
- 2015-10-06 IL IL241920A patent/IL241920A0/en unknown
-
2016
- 2016-02-22 JP JP2016030540A patent/JP2016145220A/ja not_active Withdrawn
- 2016-08-11 US US15/234,575 patent/US20170190779A1/en not_active Abandoned
- 2016-11-17 LU LU93315C patent/LU93315I2/fr unknown
- 2016-12-07 HU HUS1600050C patent/HUS1600050I1/hu unknown
- 2016-12-09 CY CY2016043C patent/CY2016043I2/el unknown
-
2017
- 2017-09-21 CY CY20171100999T patent/CY1119389T1/el unknown
-
2018
- 2018-04-18 US US15/956,458 patent/US20180237532A1/en not_active Abandoned
- 2018-07-17 HK HK18109281.9A patent/HK1249850A1/en unknown
- 2018-09-17 US US16/132,852 patent/US20190002575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508039A5 (https=) | ||
| Olsen | Interferon in the treatment of cutaneous T‐cell lymphoma | |
| CASTELLINO et al. | Latent radiation injury of lungs or heart activated by steroid withdrawal | |
| Hibi et al. | Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study | |
| Waubant et al. | Interferon beta-1a in children with multiple sclerosis is well tolerated | |
| O'Brien et al. | Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products | |
| JP2014114288A5 (https=) | ||
| Galetta et al. | US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles | |
| JP2007515469A5 (https=) | ||
| HRP950052A2 (en) | Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels | |
| JP2014533279A5 (https=) | ||
| Ruggieri et al. | Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data | |
| JP2009511480A5 (https=) | ||
| JP2021533204A5 (https=) | ||
| RU2009128659A (ru) | Фармацевтическая композиция, содержащая анти-cd6 моноклональное антитело, пригодная для диагностики и лечения ревматоидного артрита | |
| Brown et al. | A phase I clinical trial of recombinant DNA gamma interferon. | |
| JP2005535636A5 (https=) | ||
| JP2023154026A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| Neri et al. | Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-α-2a and interferon-α-2b | |
| Storz | Of patents and patent disputes: The TNFα patent files. Part 1: Humira | |
| CN1173736C (zh) | 白细胞介素-18抑制剂抑制肿瘤转移的用途 | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2006503095A5 (https=) | ||
| JP2022513098A5 (https=) |